Duocarmycin ADCs for use in treatment of endometrial cancer
AssigneesSynthon Biopharmaceuticals B.V., Yale University
InventorsAlessandro Davide Santin, Peter Johannes Goedings
Life of this patent
Estimating the term…
Abstract
The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2− or 1+ and HER2 FISH negative tumor tissue status.
Claims11
A method of treating uterine serous carcinoma expressing HER2 in a human patient, comprising administering to the patient a therapeutically effective amount of a compound having the structure
- wherein 2.5-2.9 represents an average DAR for the compound.
Dependencies are inferred from the claim text.